These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Clinical Outcomes and Prognostic Factors of Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia]. Lou D, Liu L, Yan XQ, Gu FN, Zhang YP, Qin WW. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1577-1585. PubMed ID: 36208269 [Abstract] [Full Text] [Related]
27. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia. Fleischmann M, Schnetzke U, Frietsch JJ, Sayer HG, Schrenk K, Hammersen J, Glaser A, Hilgendorf I, Hochhaus A, Scholl S. J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206 [Abstract] [Full Text] [Related]
28. Risk factors for post-transplant relapse and survival in younger adult patients with t(8;21)(q22;q22) acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: A multicenter retrospective study. Zhou W, Chen G, Gong D, Gao Y, Yu L. Front Oncol; 2023 Jun; 13():1138853. PubMed ID: 36845681 [Abstract] [Full Text] [Related]
29. [Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndromes]. Yokoyama K. Rinsho Ketsueki; 2021 Jun; 62(5):486-495. PubMed ID: 34248126 [Abstract] [Full Text] [Related]
31. Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Tong X, Li M, Jin J, Li Y, Li L, Peng Y, Huang L, Xu B, Meng F, Mao X, Huang L, Huang W, Zhang D. Int J Cancer; 2023 May 15; 152(10):2123-2133. PubMed ID: 36594582 [Abstract] [Full Text] [Related]
32. Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation. Desai A, Samara Y, Yang D, Ball B, Braun A, Koller P, Blackmon A, Agrawal V, Pourhassan H, Amanam I, Arslan S, Otoukesh S, Sandhu K, Aldoss I, Ali H, Salhotra A, Al Malki MM, Artz A, Becker P, Smith E, Stein A, Marcucci G, Forman SJ, Curtin P, Nakamura R, Pullarkat V. Leuk Res; 2024 Oct 15; 145():107565. PubMed ID: 39208597 [Abstract] [Full Text] [Related]
34. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study. Granfeldt Østgård LS, Medeiros BC, Sengeløv H, Nørgaard M, Andersen MK, Dufva IH, Friis LS, Kjeldsen E, Marcher CW, Preiss B, Severinsen M, Nørgaard JM. J Clin Oncol; 2015 Nov 01; 33(31):3641-9. PubMed ID: 26304885 [Abstract] [Full Text] [Related]
35. Outcome of therapy-related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A propensity score matched analysis. Itonaga H, Kida M, Hamamura A, Uchida N, Ozawa Y, Fukuda T, Ueda Y, Kataoka K, Katayama Y, Ota S, Matsuoka KI, Kondo T, Eto T, Kanda J, Ichinohe T, Atsuta Y, Miyazaki Y, Ishiyama K. Hematol Oncol; 2022 Oct 01; 40(4):752-762. PubMed ID: 35299289 [Abstract] [Full Text] [Related]
36. Risk Stratification and Prognosticators of Acute Myeloid Leukemia with Myelodysplasia-Related Changes in Patients Undergoing Allogeneic Stem Cell Transplantation: A Retrospective Study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Harada K, Konuma T, Machida S, Mori J, Aoki J, Uchida N, Ohashi K, Fukuda T, Tanaka M, Ikegame K, Ozawa Y, Iwato K, Eto T, Onizuka M, Ichinohe T, Atsuta Y, Yano S. Biol Blood Marrow Transplant; 2019 Sep 01; 25(9):1730-1743. PubMed ID: 31054982 [Abstract] [Full Text] [Related]
37. Pretransplantation minimal residual disease monitoring by multiparameter flow cytometry predicts outcomes of AML patients receiving allogeneic hematopoietic stem cell transplantation. Zhang Y, Wang P, Cassady K, Zou Z, Li Y, Deng X, Yang W, Peng X, Zhang X, Feng Y. Transpl Immunol; 2022 Jun 01; 72():101596. PubMed ID: 35390479 [Abstract] [Full Text] [Related]
39. Chemotherapy or Allogeneic Stem Cell Transplantation as Salvage Therapy for Patients with Refractory Acute Myeloid Leukemia: A Multicenter Analysis. Wang ZY, Gao WH, Zhao HJ, Yin CR, Wang ZW, Tian L, Wang L, Wang LN, Jiang JL, Devillier R, Wan M, Wang JM, Huang PP, Blaise D, Hu J. Acta Haematol; 2022 Jun 01; 145(4):419-429. PubMed ID: 35231903 [Abstract] [Full Text] [Related]
40. Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy. Zuanelli Brambilla C, Lobaugh SM, Ruiz JD, Dahi PB, Goldberg AD, Young JW, Gyurkocza B, Shaffer BC, Ponce DM, Tamari R, Sanchez Escamilla M, Castillo Flores N, Politikos I, Scordo M, Shah GL, Cho C, Lin RJ, Maloy MA, Devlin SM, Jakubowski AA, Berman E, Stein EM, Papadopoulos EB, Perales MA, Tallman MS, Giralt SA, Smith M. Transplant Cell Ther; 2021 Sep 01; 27(9):771.e1-771.e10. PubMed ID: 34033977 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]